Navigation Links
New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
Date:11/7/2011

coses are endemic.

Malignancies

During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients.  In CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients.  This is approximately 2-fold higher than expected in the general population.  Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy less than or equal to 18 years of age), of which CIMZIA is a member.  Approximately half of the cases were lymphoma (including Hodgkin's and non-Hodgkin's lymphoma, while the other cases represented a variety of different malignancies and included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.  Most of the patients were receiving concomitant immunosuppressants.  

Cases of acute and chronic leukemia have been reported with TNF-blocker use.  Even in the absence of TNF-blocker therapy, patients with RA may be at a higher risk (approximately 2-fold) than the general population for developing leukemia.

Heart Failure

Cases of worsening congestive heart failure (CHF) a
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
4. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
7. Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease
8. Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinsons Disease
9. Ekahau RTLS Enables Improvements in Staff Safety in Austrian Psychiatric Hospital
10. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
11. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... y LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos ... Ecografía, tiempos de examen rápidos y un flujo de ... confianza diagnóstica en el proceso de detección de Cardiopatías ... PHIA) ha anunciado hoy el lanzamiento europeo de ...
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2
... NEW YORK, Sept. 27 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer, will be presenting at the JMP Securities ... in New York City.  Mr. Bentsur,s presentation is scheduled to ... A live audio webcast of Mr. Bentsur,s presentation ...
... Mass., Sept. 25 Boston Scientific Corporation (NYSE: ... data from the HORIZONS-AMI trial.  The trial, sponsored ... support from Boston Scientific and The Medicines Company ... determine the safety and efficacy of the TAXUS® ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference 2HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients 2HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients 3HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients 4
(Date:8/31/2015)... , ... August 31, 2015 , ... ... improved airway management device that could effectively deliver oxygen with a lower risk ... find a better way, I invented the Adam Device." , The Adam Device ...
(Date:8/31/2015)... Tennessee (PRWEB) , ... August ... ... of Lifestyle Medicine (ACLM), the nation’s medical professional association for physicians and ... in conjunction with the Lifestyle Medicine Foundation, announced today the establishment of ...
(Date:8/31/2015)... ... 2015 , ... MeYou Health ®, a social well-being company and wholly ... , by including an in-app step tracker. , Walkadoo is a pedometer-based walking ... Rather than broadly assign every Walkadoo member 10,000 steps a day (as is typical ...
(Date:8/31/2015)... ACA (PRWEB) , ... August 31, 2015 , ... There’s ... growing niche in the digital healthcare industry. , Consumer driven health plans (CDHPs) ... one in an advisory and strategic role to the company, and another to answer ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... firm, introduces the Talent Management Division , a department devoted to helping ... sales department. Talent management goes beyond selection, and The Brooks Group believes in ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3
... a mechanism for resistance to paclitaxel in ovarian cancer, ... resistance. Mohamed K. Hassan, Ph.D., a postdoctoral ... as a collaborative study with his colleagues when he ... Egypt. Results of this study were presented at the ...
... , WASHINGTON , March 10 Today RetireSafe, representing 400,000 senior citizen supporters across America, urged ... pending in Congress. House and Senate "reform" efforts would ration high-quality physician hospital care to Medicare patients, as a ... ... , , ...
... of cancer, clinicians have a number of treatment options. ... tumor using an arsenal of cancer-killing therapies. Chemotherapy, where ... is a very powerful weapon in this arsenal. It ... testicular cancer and Hodgkin,s Disease, but works poorly in ...
... An independent panel convened this week by the National Institutes ... have limited access to clinicians and facilities able and willing ... because of so-called VBAC bans. Many, even those at ... not offered this option. The panel affirmed that a trial ...
... ... Independent third-party lab tests have conclusively demonstrated that ... against the most prevalent and deadly foodborne pathogens. Conducted ... Good Laboratory Practice (GLP) protocol, these tests demonstrated that BIOSECUR ...
... get the right amount of rest , ... , , ... ... ANN ARBOR, Mich. , March 10 Many Americans will lose an ...
Cached Medicine News:Health News:RetireSafe Urges All Seniors to Call on Congress to Save Physician Hospitals' Quality Care for Medicare Patients 2Health News:RetireSafe Urges All Seniors to Call on Congress to Save Physician Hospitals' Quality Care for Medicare Patients 3Health News:Exploiting the architecture of cancers may lead to their destruction 2Health News:Panel questions 'VBAC bans,' advocates expanded delivery options for women 2Health News:Panel questions 'VBAC bans,' advocates expanded delivery options for women 3Health News:Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses 2Health News:Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses 3Health News:Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses 4Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 2Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 3Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 4
... SureCut M3500 Radial Microtome has a look that ... a range of functions and capabilities that will ... on years of experience and knowledge but still ... SureCut M3500 Microtome will be the answer to ...
Clock oil, 6 grams net...
Coarse abrasive for knife sharpening, 6 grams net...
Standard vice clamp, can be fitted instead of Quick Realease Cassette...
Medicine Products: